Yu Heng Kwan1, Warren Fong2,3,4, Priscilla How5,6, Hwee-Lin Wee5,7, Ying Ying Leung2, Jie Kie Phang2, Nai Lee Lui2, Chuen Seng Tan7, Rahul Malhotra1, Truls Østbye1, Julian Thumboo8,9,10. 1. Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore. 2. Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore. 3. Duke-NUS Medical School, Singapore, Singapore. 4. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 5. Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore. 6. Division of Nephrology, Department of Medicine, National University Hospital, Singapore, Singapore. 7. Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. 8. Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore. julian.thumboo@singhealth.com.sg. 9. Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore. julian.thumboo@singhealth.com.sg. 10. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. julian.thumboo@singhealth.com.sg.
Abstract
PURPOSE: The purpose of the study was to assess the impact of axial spondyloarthritis (axSpA) on patients' quality of life (QoL) compared to patients with moderate to end-stage chronic kidney disease (CKD). METHODS: We conducted secondary analysis of QoL data obtained from patients with axSpA and CKD from 2011 to 2014. QoL was assessed using the SF-36 version 2 and KDQoL-SF for patients with axSpA and CKD, respectively. Patients with CKD were subcategorized to CKD-pre-dialysis, hemodialysis (CKD-HD) and peritoneal dialysis (CKD-PD). Linear regression was used to compare QoL between patients with axSpA and CKD after adjusting for age, gender, ethnicity, education level, and marital status. RESULTS: A total of 765 patients (mean age 54.6, 63.0% males, 69.0% Chinese) were analyzed, of which 188 (24.5%) had axSpA. Patients with axSpA had poorer SF-36 bodily pain (BP) scores (axSpA: reference; CKD-pre-dialysis β: 11.04, p < 0.001; CKD-HD β: 9.52, p < 0.001; CKD-PD β: 10.35, p < 0.001) and higher general health scores (axSpA: reference; CKD-pre-dialysis β: - 7.87, p < 0.001; CKD-HD β: - 7.14, p < 0.001, CKD-PD β: - 7.25, p < 0.001) as compared to patients with CKD. Generally, patients with axSpA had poorer SF-36 scores than patients with CKD-pre-dialysis and similar SF-36 scores compared to patients with CKD-HD or CKD-PD. CONCLUSIONS: The burden of axSpA on QoL is not trivial and is comparable to patients with CKD-HD or CKD-PD.
PURPOSE: The purpose of the study was to assess the impact of axial spondyloarthritis (axSpA) on patients' quality of life (QoL) compared to patients with moderate to end-stage chronic kidney disease (CKD). METHODS: We conducted secondary analysis of QoL data obtained from patients with axSpA and CKD from 2011 to 2014. QoL was assessed using the SF-36 version 2 and KDQoL-SF for patients with axSpA and CKD, respectively. Patients with CKD were subcategorized to CKD-pre-dialysis, hemodialysis (CKD-HD) and peritoneal dialysis (CKD-PD). Linear regression was used to compare QoL between patients with axSpA and CKD after adjusting for age, gender, ethnicity, education level, and marital status. RESULTS: A total of 765 patients (mean age 54.6, 63.0% males, 69.0% Chinese) were analyzed, of which 188 (24.5%) had axSpA. Patients with axSpA had poorer SF-36 bodily pain (BP) scores (axSpA: reference; CKD-pre-dialysis β: 11.04, p < 0.001; CKD-HD β: 9.52, p < 0.001; CKD-PD β: 10.35, p < 0.001) and higher general health scores (axSpA: reference; CKD-pre-dialysis β: - 7.87, p < 0.001; CKD-HD β: - 7.14, p < 0.001, CKD-PD β: - 7.25, p < 0.001) as compared to patients with CKD. Generally, patients with axSpA had poorer SF-36 scores than patients with CKD-pre-dialysis and similar SF-36 scores compared to patients with CKD-HD or CKD-PD. CONCLUSIONS: The burden of axSpA on QoL is not trivial and is comparable to patients with CKD-HD or CKD-PD.
Authors: Michael M Ward; Atul Deodhar; Elie A Akl; Andrew Lui; Joerg Ermann; Lianne S Gensler; Judith A Smith; David Borenstein; Jayme Hiratzka; Pamela F Weiss; Robert D Inman; Vikas Majithia; Nigil Haroon; Walter P Maksymowych; Janet Joyce; Bruce M Clark; Robert A Colbert; Mark P Figgie; David S Hallegua; Pamela E Prete; James T Rosenbaum; Judith A Stebulis; Filip van den Bosch; David T Y Yu; Amy S Miller; John D Reveille; Liron Caplan Journal: Arthritis Rheumatol Date: 2015-09-24 Impact factor: 10.995
Authors: M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper Journal: Ann Rheum Dis Date: 2009-03-17 Impact factor: 19.103